ClinicalTrials.gg
Not yet recruitingNCT07681297TIBECUpdated Jul 10, 2026

Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease

A Phase 1/2 interventional study of Tislelizumab + Bevacizumab + Capecitabine in Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC) and CNS Disease, sponsored by National University Hospital, Singapore. Not yet recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by National University Hospital, Singapore · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
154
Allocation
Non-randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing tislelizumab in Triple Negative Breast Neoplasms — 6 open to participants now, 8 under way, none of them phase 3. tislelizumab · Triple Negative Breast Neoplasms.

Planned enrollment
4th of 12
154 · median 65
Started
2026
the only one that year
Phase 1/2
3 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
1 of 12
National University Hospital, Singapore

Among the 12 studies testing tislelizumab in Triple Negative Breast Neoplasms, this one is the 4th largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 1/2, and was the 11th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

6 of the 12 studies testing tislelizumab in Triple Negative Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tislelizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This study is designed to establish the safety of the combination of PD-1 inhibitor tislelizumab, an anti-angiogenic agent bevacizumab and a chemotherapeutic agent capecitabine, in a phase Ib setting and to evaluate preliminary efficacy in selected expansion cohorts, including PD-L1-negative metastatic triple negative breast cancer (TNBC) and patients with active CNS disease. A sequential approach to cohort expansion will allow further evaluation in hormone receptor positive (HR+), HER2 negative (HER2-) disease if a signal of activity is observed in PD-L1 negative TNBC.

03

Conditions studied

  • Advanced Solid Tumor Cancer
  • Triple-Negative Breast Cancer (TNBC)
  • CNS Disease
  • Breast Cancer

Keywords

  • Tislelizumab
  • Bevacizumab
  • Capecitabine
  • Breast Cancer
  • Advanced Solid Tumour Cancer
  • CNS disease
  • Triple-Negative Breast Cancer (TNBC)
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible for enrolment if they meet all applicable general inclusion criteria and, where relevant, the cohort-specific inclusion criteria.

  1. General Inclusion Criteria

    • Age 21 years or older at the time of .
    • or cytologically confirmed advanced or solid tumor.
    • Patients must have received at least one prior line of standard systemic therapy for locally advanced/unresectable or metastatic disease, OR be ineligible for, intolerant of, or have declined standard-of-care therapy, with the specific reason documented in the source records.
    • (ECOG) performance status of 0 or 1.
    • Estimated of at least 12 weeks.
    • At least one evaluable (measurable or non-measurable) lesion as defined by version 1.1, unless otherwise specified for a disease-specific cohort.
    • Recovery to Grade 1 or baseline from acute toxicities of prior anti-cancer therapy, except for alopecia, vitiligo, or other toxicities deemed not by the investigator.
    • Adequate organ and marrow function within 14 days prior to first dose of study treatment, defined as follows:

      1. ≥1.5 × 10\^9/L
      2. count ≥100 × 10\^9/L
      3. ≥9.0 g/dL
      4. Total \<1.5 × , except in patients with known Gilbert's syndrome, in whom total bilirubin up to 3.0 × upper limit of normal is permitted provided direct bilirubin is within normal limits
      5. and ALT \<2.5 × upper limit of normal, or \<5 × upper limit of normal in the presence of liver metastases
      6. Calculated ≥50 mL/min (calculated using the Cockcroft-Gault formula)
      7. Urine protein dipstick \<2+, or if urine dipstick is 2+ or greater, 24-hour urine protein \<1 g per 24 hours
    • Adequately controlled blood pressure (systolic \<150mmHg, diastolic \<100mmHg) with or without anti-hypertensive medication.
    • Able to swallow and retain oral medication.
    • Able to understand and willing to sign written informed consent.
    • Willing and able to comply with study visits, treatment plan, laboratory tests, imaging, and other protocol-required procedures.
    • Prior exposure to , anti-angiogenic therapy, or fluoropyrimidines is permitted, unless prohibited by cohort-specific criteria.
  2. TNBC Cohort Inclusion Criteria

    • Histologically confirmed triple-negative breast cancer, defined as estrogen receptor \<1%, progesterone receptor \<1%, and -negative according to current ASCO/CAP guidelines.
    • Metastatic or unresectable locally advanced disease not amenable to curative treatment.
    • PD-L1-negative disease, defined as combined positive score (CPS) \<10 using an approved assay.
    • Candidate for systemic therapy for metastatic disease.
    • Patients must have measurable or non-measurable but evaluable disease per RECIST v1.1.
    • Patients without may be enrolled provided they have unequivocal non-measurable disease that can be adequately assessed or disease status on serial radiologic evaluations, in the opinion of the investigator.
    • Prior or adjuvant chemotherapy is permitted.
    • Prior immune checkpoint inhibitor therapy in the neoadjuvant or adjuvant setting is permitted, provided it was completed at least 12 months prior to start of study treatment.
    • Prior capecitabine is permitted only in the adjuvant setting, provided it was completed at least 12 months prior to start of study treatment.
    • Patients with prior CNS disease are eligible only if CNS disease is clinically controlled, defined as asymptomatic or minimally symptomatic, does not require and does not require ongoing CNS-directed therapy.
  3. CNS Cohort Inclusion Criteria

    • Histologically or cytologically confirmed advanced solid tumor.
    • Progressive .
    • At least one measurable CNS lesion.
    • is allowed.
    • Patients receiving corticosteroids for management of CNS disease or CNS-related symptoms are eligible provided the corticosteroid dose is stable or decreasing for at least 7 days prior to first dose of study treatment.
    • Patients with driver mutations (e.g., EGFR-mutant or ALK-rearranged NSCLC, HER2+ metastatic breast cancer) must have received at least one prior line of matched systemic therapy, unless such therapy is , not tolerated, unavailable, or the patient is otherwise unsuitable in the investigator's judgment.
  4. HR-Positive/HER2-Negative Cohort Inclusion Criteria

    • Histologically confirmed hormone receptor-positive (defined as ER>1% or PR>1%), HER2-negative metastatic or unresectable locally advanced breast cancer not amenable to curative treatment.
    • Patients must have measurable or non-measurable but evaluable disease per RECIST v1.1.
    • Patients without measurable disease may be enrolled provided they have unequivocal non-measurable disease that can be adequately assessed or disease status on serial radiologic evaluations, in the opinion of the investigator.
    • Prior failure of at least one line of endocrine therapy in the advanced or metastatic setting, unless deemed endocrine-resistant in the opinion of the investigator.
    • Up to one prior line of palliative chemotherapy is permitted.
    • If prior capecitabine was given, it must not have been administered in the metastatic setting and must have been completed >12 months prior to study entry.
    • Any CNS disease must be clinically controlled, defined as asymptomatic or minimally symptomatic, must not require corticosteroids, and must not require ongoing CNS-directed therapy.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded if they meet any applicable general exclusion criterion or any relevant cohort-specific exclusion criterion.

  1. General Exclusion Criteria

    • Treatment with an agent within 14 days prior to first dose of study treatment.
    • Known or to tislelizumab, bevacizumab, capecitabine, fluoropyrimidines, or any of the study drugs.
    • Known dihydropyrimidine dehydrogenase deficiency.
    • Uncontrolled or clinically unstable CNS disease, including poor performance status attributable to CNS disease, ongoing requirement for escalating , uncontrolled seizures, or rapid neurologic deterioration.
    • Clinically significant cardiovascular disease, including uncontrolled hypertension, unstable angina, clinically significant arrhythmia, myocardial infarction, or stroke that is of clinical concern in the opinion of the investigator.
    • Significant bleeding risk or recent clinically significant hemorrhage.
    • History of gastrointestinal perforation, fistula, or intra-abdominal abscess within 6 months prior to first dose, or other conditions conferring high risk in the opinion of the investigator.
    • Non-healing wound, active ulcer, or untreated fracture.
    • Active infection requiring systemic therapy.
    • Active disease requiring systemic treatment within the past 2 years, with exceptions such as replacement therapy or other conditions judged unlikely to recur.
    • Current use of systemic immunosuppressive medication, excluding physiologic corticosteroid replacement or other permitted low-dose steroids.
    • Active pneumonitis or interstitial lung disease requiring treatment, or other clinically significant pulmonary condition that, in the opinion of the investigator, would increase the risk of study treatment.
    • Other active requiring treatment or likely to interfere with assessment of study endpoints, in the opinion of the investigator.
    • Pregnancy or breastfeeding.
    • Any serious medical, psychiatric, or social condition that, in the opinion of the investigator, would compromise patient safety, interfere with study participation, or confound interpretation of study results.
  2. TNBC Cohort Exclusion Criteria

    • Prior systemic therapy for TNBC.
    • Prior capecitabine in the metastatic setting.
    • Progressive CNS disease. Patients with progressive CNS disease should be enrolled into the CNS cohort instead.
  3. CNS Cohort Exclusion Criteria

    • Severely symptomatic or clinically unstable CNS disease, including rapid neurologic deterioration, uncontrolled seizures, or requirement for rapidly escalating corticosteroids.
    • CNS disease requiring immediate neurosurgical intervention or urgent radiation therapy, in the opinion of the investigator.
    • Stereotactic radiosurgery (SRS) including gamma knife, within 7 days before the first dose of study treatment.
    • Whole brain radiotherapy (WBRT) within 21 days before the first dose of study treatment.
    • Use of , bevacizumab, and/or capecitabine within 6 months before the first dose of study treatment.
  4. HR-Positive/-Negative Cohort Exclusion Criteria

    • More than one prior line of palliative chemotherapy.
    • Progressive CNS disease. Patients with progressive CNS disease should be enrolled into the CNS cohort instead.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    Phase Ib: Dose-Finding / Safety Confirmation

    Patients with advanced solid tumors will be enrolled into a standard 3+3 design. Dose escalation will proceed using two predefined dose levels (DL1 and DL-1). There will be no dose reductions permitted for either tislelizumab or bevacizumab; dose modifications, if required, will apply only to capecitabine in accordance with protocol-defined guidelines. If the DL-1 dose level is not tolerated, further dose de-escalation is not pre-specified. In such a scenario, a formal review will be undertaken in consultation with the Study's Scientific Committee to determine the appropriate next steps, including consideration of additional dose reduction strategies or discontinuation of further dose exploration for the combination.

    Drug: Tislelizumab + Bevacizumab + Capecitabine

  • Experimental
    Phase II: Multi-Cohort Expansion - PD-L1 negative TNBC cohort

    Drug: Tislelizumab + Bevacizumab + Capecitabine

  • Experimental
    Phase II: Multi-Cohort Expansion - Active CNS disease cohort

    Drug: Tislelizumab + Bevacizumab + Capecitabine

  • Experimental
    Phase II: Multi-Cohort Expansion - HR+/HER2- MBC cohort

    Drug: Tislelizumab + Bevacizumab + Capecitabine

Interventions

  • DrugTislelizumab + Bevacizumab + Capecitabine

    Drug pages: TislelizumabStudies of TislelizumabTislelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BevacizumabStudies of BevacizumabBevacizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CapecitabineStudies of CapecitabineCapecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Phase Ib Dose Levels Dose Level DL1 (Starting Dose) * Tislelizumab: 200 mg IV Day 1 q3w * Bevacizumab: 7.5 mg/kg IV Day 1 q3w * Capecitabine: 1000 mg/m² PO BID Days 1-14 q3w DL-1 (De-escalation) * Tislelizumab: 200 mg IV Day 1 q3w * Bevacizumab: 7.5 mg/kg IV Day 1 q3w * Capecitabine: 800 mg/m² PO BID Days 1-14 q3w

06

What researchers measure

Primary outcomes

  1. Phase Ib: Number and percentage of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: 2 years

  2. Phase Ib: Phase II recommended dose of capecitabine in combination with tislelizumab and bevacizumab

    Time frame: 2 years

  3. Phase II TNBC Cohort: 12-month progression-free survival rate with tislelizumab, bevacizumab and capecitabine

    Time frame: 12 months

  4. Phase II CNS Cohort: Intracranial objective response rate with tislelizumab, bevacizumab and capecitabine

    Time frame: 2 years

  5. Phase II HR-positive/HER2-negative Cohort (if activated): 12-month progression-free survival rate with tislelizumab, bevacizumab, and capecitabine.

    Time frame: 12 months

Secondary outcomes

  1. Phase Ib: Incidence and severity of adverse events (AEs), including serious adverse events (SAEs) and immune-related adverse events (irAEs)

    Time frame: 2 years

  2. Phase II (TNBC, HR+/HER2- MBC): Objective response rate (ORR)

    Time frame: 2 years

  3. Phase II (TNBC, HR+/HER2- MBC): Disease control rate (DCR)

    Time frame: 2 years

  4. Phase II (TNBC, HR+/HER2- MBC): Duration of response (DoR)

    Time frame: 2 years

  5. Phase II (TNBC, HR+/HER2- MBC): Median progression-free survival (PFS)

    Time frame: 2 years

  6. Phase II (TNBC, HR+/HER2- MBC): Overall survival (OS)

    Time frame: 2 years

  7. Phase II CNS Cohort: Intracranial progression-free survival (iPFS)

    Time frame: 2 years

  8. Phase II CNS Cohort: Objective response rate (ORR) in extracranial sites

    Time frame: 2 years

  9. Phase II CNS Cohort: Disease control rate (DCR) in extracranial sites

    Time frame: 2 years

  10. Phase II CNS Cohort: Median progression-free survival (PFS) in extracranial sites

    Time frame: 2 years

  11. Phase II CNS Cohort: Overall survival (OS)

    Time frame: 2 years

Other outcomes

  1. All Phases and Cohorts: Association between tumor genetic biomarkers and treatment response (ORR, DCR, PFS)

    Time frame: 2 years

  2. All Phases and Cohorts: Association between tumor immunohistochemistry biomarkers and treatment response (ORR, DCR, PFS)

    Time frame: 2 years

  3. All Phases and Cohorts: Association between plasma protein biomarkers and treatment response (ORR, DCR, PFS)

    Time frame: 2 years

  4. All Phases and Cohorts: Association between circulating tumor DNA (ctDNA) levels and treatment response (ORR, DCR, PFS)

    Time frame: 2 years

  5. All Phases and Cohorts: Association between germline pharmacogenetics and treatment response (ORR, DCR, PFS)

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Publications

  • Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2. PubMed 22658128 ↗
  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2. PubMed 22658127 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

Of 118 phase 1/2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 79. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jul 2, 2026
StartEst.
Aug 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07681297
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Jul 10, 2026

Study contacts

Soo Chin Lee
Contact
soo_chin_lee@nuhs.edu.sg
+6567724621
Soo Chin Lee
principal investigator · National University Hospital, Singapore

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Bevacizumab · Capecitabine

Start the discussion